HTL expands medical division and creates jobs

HTL-Strefa group, which claims to supply half the world’s current disposable lancet market, has been given the official go-ahead to install a technologically advanced assembly line for insulin needle products. In January, the firm was granted a new permit to grow the operation located in Poland’s Lodz Special Economic Zone.

Group subsidiary HTL, which runs the 6,500 square metre Ozorków site, intends to create a total of 18 new jobs following the latest investment there. The site also houses the HTL-Strefa headquarters.

The plant, one of two owned by the group in Poland, makes personal lancets for home use by patients such as diabetics and assembles safety lancets for blood sampling. It also has a class 100,000 clean room moulding facility.

The second operation, run by HTL Lancet in Leczyca moulds plastic components, grinds needles and makes springs for the disposable safety lancets. The unit, set up in 2006 also in the Lodz SEZ, covers an area of 7,300 square metres.

In addition, HTL-Strefa has sales and customer service operations in Warsaw, Frankfurt and in Atlanta in the US.

This latest project is the third industrial investment HTL-Strefa has made in the region. It has already created 950 jobs at an overall cost of €29m, according to Palilz, the Polish Information and Foreign Investment Agency.

HTL-Strefa was transformed into a joint stock company in May 2006, and has since then been listed on the Warsaw Stock Exchange. The group is owned by the Stockholm-based private equity firm EQT Partners.

[ Back ]